Imagine a world where a silent, progressive autoimmune disease like IgA nephropathy could be tackled at its root cause, offering hope to those diagnosed with it. This is the vision that Takeda, a leading biopharmaceutical company, is striving to bring to life. And the latest data from their Phase 1b study on mezagitamab (TAK-079) is a significant step forward in this journey.
The study, presented at the American Society of Nephrology (ASN) Kidney Week 2025, revealed that mezagitamab, an anti-CD38 monoclonal antibody, has the potential to stabilize kidney function in patients with IgA nephropathy, even up to 18 months after the last dose. This is a remarkable finding, considering the progressive nature of the disease, which often goes unnoticed until significant kidney damage has occurred.
But here's where it gets controversial...
IgA nephropathy, a lifelong autoimmune disease, is usually diagnosed in young adults aged 10-30. It's caused by immune complexes depositing inside the kidney filters, leading to inflammation and irreversible kidney damage. Despite available treatments, about one in five patients experience renal failure within a decade of diagnosis.
Mezagitamab works by targeting the underlying immune mechanisms of IgA nephropathy. By depleting cells that produce an abnormal protein called Gd-IgA1, implicated in the disease's pathogenesis, mezagitamab aims to halt the disease process early on.
The results from the Phase 1b study are promising. Out of the 17 patients treated with mezagitamab as an add-on to their stable background therapy, 13 continued into the long-term follow-up period. At Week 96, kidney function remained stable, with a mean change in eGFR from baseline of +2.5. Patients also sustained a significant reduction in proteinuria, a key indicator of kidney health.
And this is the part most people miss...
Mezagitamab was generally well-tolerated, with no serious adverse events reported. This is crucial, as it suggests that the treatment is not only effective but also safe.
Obi Umeh, M.D., M.Sc., Vice President and Franchise Global Program Leader at Takeda, believes that these data reinforce the potential of mezagitamab to revolutionize the treatment of autoimmune diseases like IgA nephropathy. With patient enrollment ongoing in Phase 3 trials for IgA nephropathy and immune thrombocytopenia, Takeda is committed to bringing innovative solutions to patients with high unmet needs.
Mezagitamab is currently in Phase 3 clinical development for both primary IgA nephropathy and chronic immune thrombocytopenia. In October 2025, it received Orphan Drug Designation from the European Medicines Agency for primary IgA nephropathy, and in August 2025, it was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for chronic immune thrombocytopenia.
So, what does the future hold for mezagitamab? Only time will tell, but with these promising results, it's an exciting prospect for patients and healthcare professionals alike.
What are your thoughts on this potential game-changer in autoimmune disease treatment? Do you think mezagitamab could be a breakthrough therapy? Share your insights and let's spark a discussion!
